Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. Yam C, et al. Invest New Drugs. 2018 Apr;36(2):299-306. doi: 10.1007/s10637-018-0564-2. Epub 2018 Jan 27. Invest New Drugs. 2018. PMID: 29374384 Clinical Trial.
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Basho RK, et al. Among authors: yam c. Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23. Oncologist. 2018. PMID: 30139837 Free PMC article.
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.
Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. Yam C, et al. Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11. Invest New Drugs. 2018. PMID: 30311036 Clinical Trial.
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Yam C, et al. Invest New Drugs. 2019 Apr;37(2):345-351. doi: 10.1007/s10637-018-0700-z. Epub 2019 Jan 5. Invest New Drugs. 2019. PMID: 30610588 Clinical Trial.
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. Yam C, et al. Invest New Drugs. 2021 Apr;39(2):509-515. doi: 10.1007/s10637-020-00995-2. Epub 2020 Sep 28. Invest New Drugs. 2021. PMID: 32984932 Clinical Trial.
293 results